Microvessels and Heart Problems in Sickle Cell Disease
Microvascular and Cardiac Dysfunction in Sickle Cell Disease
Background:
- Small blood vessels (microvessels) in many different organs are affected by diseases such as diabetes and atherosclerosis. These microvessels may also be abnormal in people who have sickle cell disease. Stiffness of the red blood cells leads to problems in the microvessels of the heart and kidneys. However, these problems may not be detected until these organs are severely affected. Researchers want to study problems with microvessels in people with and without sickle cell disease.
Objectives:
- To study how microvessels in the heart and other organs are affected by sickle cell disease.
Eligibility:
- Individuals at least 18 years of age who have sickle cell disease.
- Healthy volunteers at least 18 years of age.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected.
- All participants will have about 3 to 4 hours of testing for the study. Participants with sickle cell disease who are having a pain crisis at the time they enter the study may be asked to have the testing again when the crisis is over. The repeat testing will occur at least 4 weeks after the pain crisis ends.
- All participants will have the following tests:
- Blood draws to check kidney and liver function, and other blood tests
- Measure of blood flow in the brachial (upper arm) artery
- Heart ultrasound
- Ultrasound scans of arm muscles to study blood flow
- Ultrasound scans after taking vasodilators to increase blood flow
- Healthy volunteers will also have a magnetic resonance imaging scan. It will show blood flow in the heart. This scan will involve another dose of a vasodilator.
調査の概要
状態
条件
詳細な説明
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Maryland
-
Bethesda、Maryland、アメリカ、20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
- INCLUSION CRITERIA:
- Adult subject age greater than or equal to 18 years
- Able to give written informed consent
- For SCD groups, must have confirmed diagnosis of sickle cell disease
EXCLUSION CRITERIA:
- Atrial fibrillation or other irregular rhythm that would preclude adequate image acquisition
- Subjects with a contraindication for the ultrasound contrast agent.
- Pregnant or lactating women
- Known obstructive coronary or peripheral vascular disease
- SCD subjects at steady-state must not have acute pain crisis requiring intravenous analgesics within the prior 4 weeks
- SCD subjects in crisis must be within 72 hours of hospital admission
- Subjects with contraindications to MRI scanning will complete all other procedures but will not undergo the MRI scan. Subjects with an estimated glomerular filtration rate of <30 ml/min/1.73 m(2) will not receive gadolinium as per 2011 NHLBI gadolinium administration policy.
- Subjects with a contraindication to regadenson
- Any condition that in the clinical opinion of the investigators renders study procedures inadvisable.
Diagnosis of acute chest syndrome is not an exclusion criteria for this protocol. Subjects may be concurrently enrolled in any other protocols with the exception of investigational new drug studies.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 時間の展望:見込みのある
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
|---|
|
To use contrast-enhanced ultrasound to evaluate microvascular blood flow (MBF) and capillary RBC velocity (CBV) in skeletal muscle and the heart (at rest and during vasodilator stress) in patients with SCD in comparison to normal control patient...
|
二次結果の測定
結果測定 |
|---|
|
To determine whether MBF and CBV worsen during pain crisis in patients with SCD
|
|
To determine the relation between MBF and CBV and brachial artery flow or LV dysfunction.
|
協力者と研究者
捜査官
- 主任研究者:Vandana Sachdev, M.D.、National Heart, Lung, and Blood Institute (NHLBI)
出版物と役立つリンク
一般刊行物
- Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol. 2009 Sep;84(9):618-25. doi: 10.1002/ajh.21475.
- Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004 Mar;11(2):129-51.
- Morris CR, Kuypers FA, Larkin S, Vichinsky EP, Styles LA. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol. 2000 Nov-Dec;22(6):515-20. doi: 10.1097/00043426-200011000-00009.
- Sachdev V, Sidenko S, Wu MD, Minniti CP, Hannoush H, Brenneman CL, Waclawiw MA, Arai AE, Schechter AN, Kato GJ, Lindner JR. Skeletal and myocardial microvascular blood flow in hydroxycarbamide-treated patients with sickle cell disease. Br J Haematol. 2017 Nov;179(4):648-656. doi: 10.1111/bjh.14918. Epub 2017 Sep 7.
研究記録日
主要日程の研究
研究開始
研究の完了
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。